

Dear

FREEDOM OF INFORMATION – CANCER PRESCRIBING

I write in response to your request for information in relation to cancer prescribing within NHS Lothian.

Question:

1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage) :
 - a. Avelumab + Axitinib
 - b. Axinitib
 - c. Cabozantinib
 - d. Everolimus
 - e. Lenvatinib + Everolimus
 - f. Nivolumab monotherapy
 - g. Nivolumab + Cabozantinib
 - h. Nivolumab + Ipilimumab
 - i. Pazopanib
 - j. Pembrolizumab monotherapy
 - k. Pembrolizumab + Lenvatinib
 - l. Pembrolizumab + Axitinib
 - m. Radiotherapy only
 - n. Sunitinib
 - o. Temsirolimus
 - p. Tivozanib
 - q. Other active systemic anti-cancer therapy
 - r. Palliative care only

Answer:

1a	Avelumab + Axitinib	0
1b	Axinitib	14
1c	Cabozantinib	10
1d	Everolimus	5<

1e	Lenvantinib + Everolimus	9
1f	Nivolumab monotherapy	5<
1g	Nivolumab + Cabozantinib	9
1h	Nivolumab + Ipilimumab	0
1i	Pazopanib	6
1j	Pembrolizumab monotherapy	13
1k	Pembrolizumab + Lenvatinib	5<
1l	Pembrolizumab + Axitinib	8
1m	Radiotherapy only	N/A
1n	Sunitinib	10
1o	Temsirolimus	0
1p	Tivozanib	9
1q	Other active systemic anti-cancer therapy	0
1r	Palliative care only	N/A

Question:

2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :

- a. Cobimetinib
- b. Dabrafenib
- c. Dabrafenib + Trametinib
- d. Dacarbazine
- e. Denosumab
- f. Encorafenib + Binimetinib
- g. Ipilimumab monotherapy
- h. Ipilimumab + Nivolumab
- i. Nivolumab monotherapy
- j. Nivolumab + Relatlimab
- k. Pembrolizumab
- l. Trametinib
- m. Vemurafenib
- n. Vemurafenib + Cobimetinib
- o. Other active systemic anti-cancer therapy
- p. Palliative care only

Answer:

2a	Cobimetinib	0
2b	Dabrafenib	5<
2c	Dabrafenib + Trametinib	21
2d	Dacarbazine	0

2e	Denosumab	0
2f	Encorafenib + Binimetinib	19
2g	Ipilimumab monotherapy	5<
2h	Ipilimumab + Nivolumab	5<
2i	Nivolumab monotherapy	5<
2j	Nivolumab + Relatlimab	0
2k	Pembrolizumab	27
2l	Trametinib	0
2m	Vemurafenib	0
2n	Vemurafenib + Cobimetinib	0
2o	Other active systemic anti-cancer therapy	5<
2p	Palliative care only	N/A

Question:

3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

- a. Ipilimumab monotherapy
- b. Ipilimumab + Nivolumab
- c. Nivolumab monotherapy
- d. Nivolumab + Relatlimab
- e. Pembrolizumab
- f. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
- g. Other active systemic anti-cancer therapy
- h. Palliative care only

Answer:

3a	Ipilimumab monotherapy	5<
3b	Ipilimumab + Nivolumab	5<
3c	Nivolumab monotherapy	5<
3d	Nivolumab + Relatlimab	0
3e	Pembrolizumab	12
3f	Any Targeted Therapy (<i>Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib</i>)	32
3g	Other active systemic anti-cancer therapy	5<
3h	Palliative care only	N/A

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the tables above. Since we do not have their consent to release this data from their records,

the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing, Midwifery and AHPs
Cc: Chief Executive